Resources for PatientsWith Urinary Incontinence
Urinary incontinence affects as many as 22% of men aged 65 years and older1 and 50%of postmenopausal women.2 Yet many patients are reluctant to seek treatment of theirsymptoms, even though the impact on quality of life is significant.
Urinary incontinence affects as many as 22% of men aged 65 years and older1 and 50%of postmenopausal women.2 Yet many patients are reluctant to seek treatment of theirsymptoms, even though the impact on quality of life is significant.Where can patients with urinary incontinence and their families turn for support andinformation on symptoms and treatment? Listed here are organizations that offer programsand services; a short list of publications available on a government Web site is provided aswell.3
References:
REFERENCES:
1.
Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence.
Obstet Gynecol.
2001;98:398-406.
2.
Brown JS, Grady D, Ouslander JG, et al. Prevalence of urinary incontinence and associated risk factors in postmenopausalwomen. Heart & Estrogen/Progestin Replacement Study (HERS) Research Group.
Obstet Gynecol.
1999;94:66-70.
3.
National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). Incontinence information page. Availableat: http://kidney.niddk.nih.gov/kudiseases/topics/incontinence.asp. Accessed May 18, 2004.
FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial
January 9th 2025Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.
